Semaglutide is evaluated in numerous clinical trials across early to late developmental phases, sponsored by pharmaceutical companies such as Novo Nordisk A/S, academic institutions, and governmental bodies like the National Institute on Drug Abuse. These studies primarily focus on type 2 diabetes mellitus and obesity, but also extend to conditions including alcohol use disorder, prediabetes in schizophrenia, and hypertriglyceridemia-induced acute pancreatitis. Across these investigations, recruitment statuses range from completed and active non-recruiting protocols to ongoing recruitment and studies not yet recruiting.
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT07772960 | NOT_YET_RECRUITING | Alcohol Use Disorder (AUD); Obesity (BMI Equal to or >30) |
Yale University |
2026-10-01 | PHASE1 |
| NCT06977438 | NOT_YET_RECRUITING | Obesity, Childhood |
University of Minnesota |
2026-10-01 | PHASE4 |
| NCT07731256 | NOT_YET_RECRUITING | Lower Back Pain; Obesity (BMI>30); Chronic Lower Back Pain; glp1 Agonist |
Washington University School of Medicine |
2027-02-01 | PHASE2 |
| NCT06934655 | RECRUITING | Pediatric Obesity; Metabolic and Bariatric Surgery; Semaglutide |
Children's Hospital Los Angeles |
2026-09-01 | PHASE3 |
| NCT07135245 | NOT_YET_RECRUITING | Alzheimer Disease (AD) |
Rune Skovgaard Rasmussen |
2026-01-01 | PHASE2 |
| NCT07090343 | NOT_YET_RECRUITING | Aortic Stenosis; Heart Failure |
Leiden University Medical Center |
2026-04-01 | PHASE3 |
| NCT07797036 | NOT_YET_RECRUITING | Gestational Diabetes Mellitus (GDM); Metabolic Syndrome |
University of Massachusetts, Worcester |
2027-09-01 | PHASE2; PHASE3 |
| NCT07642635 | NOT_YET_RECRUITING | Duchenne Muscular Dystrophy (DMD) |
Vanderbilt University Medical Center |
2026-09-01 | PHASE1; PHASE2 |
| NCT07770282 | NOT_YET_RECRUITING | Schizophrenia Disorder; Metabolic Syndrome; Antipsychotic-induced Weight Gain; Cardiovascular Risk; Insulin Resistance |
All India Institute of Medical Sciences, Bhubaneswar |
2026-12-01 | PHASE3 |
| NCT07586150 | NOT_YET_RECRUITING | Severe Mental Illness; Depression / Major Depressive Disorder; Bipolar Disorder (BD); Schizophrenia |
Ludwig-Maximilians - University of Munich |
2028-10 | |
| NCT07361874 | RECRUITING | Mild Autonomous Cortisol Secretion (MACS); Autonomous Cortisol Secretion (ACS); Subclinical Cushing's; Mild Autonomous Cortisol Excess |
University of Texas Southwestern Medical Center |
2026-03-05 | |
| NCT05829460 | WITHDRAWN | Endometrial Hyperplasia |
Washington University School of Medicine |
2025-03-12 | PHASE2 |
| NCT07253285 | RECRUITING | Overweight; Obesity |
Novo Nordisk A/S |
2026-01-08 | PHASE3 |
| NCT07204249 | RECRUITING | Methamphetamine-dependence |
San Francisco Department of Public Health |
2026-02-26 | PHASE2 |
| NCT07760948 | NOT_YET_RECRUITING | Type 2 Diabetes Mellitus (T2DM); Sarcopenia; Obesity; Muscle Loss; Older Adults |
Vanderbilt University Medical Center |
2026-12-01 | PHASE2 |
| NCT06975111 | RECRUITING | Menopause; Menopause Hot Flashes; Menopause Related Conditions; Cardiovascular |
University of Colorado, Denver |
2026-03-01 | PHASE2; PHASE3 |
| NCT07221214 | RECRUITING | HIV; Alcohol; Smoking Cigarette; Cardiovascular Disease Prevention |
Vanderbilt University Medical Center |
2026-04-17 | PHASE2 |
| NCT07282613 | NOT_YET_RECRUITING | Diabetes Mellitus, Type 2 |
Novo Nordisk A/S |
2026-08-04 | PHASE3 |
| NCT06885736 | RECRUITING | Obesity |
Dasman Diabetes Institute |
2025-08-07 | |
| NCT06082063 | RECRUITING | Cardiovascular Diseases; Heart Failure; Type 1 Diabetes; Kidney Failure |
Steno Diabetes Center Copenhagen |
2024-07-01 | PHASE3 |
| NCT07430332 | NOT_YET_RECRUITING | Stage 1 Diabetes Mellitus, Type 1 |
Children's Hospital Medical Center, Cincinnati |
2027-09-01 | PHASE2 |
| NCT07485062 | NOT_YET_RECRUITING | Type 2 Diabetes; Cognitive Decline in Older Adults |
Western University, Canada |
2026-09-01 | PHASE4 |
| NCT04822181 | ACTIVE_NOT_RECRUITING | Non-alcoholic Steatohepatitis |
Novo Nordisk A/S |
2021-04-01 | PHASE3 |
| NCT07547878 | NOT_YET_RECRUITING | Chronic Kidney Disease; Type 2 Diabetes |
Baylor Research Institute |
2026-04-30 | PHASE4 |
| NCT07218354 | RECRUITING | Alcohol Use Disorder |
VA Office of Research and Development |
2026-07-28 | PHASE3 |
| NCT07227948 | RECRUITING | Cocaine Use Disorder |
The University of Texas Health Science Center, Houston |
2026-01-15 | PHASE2 |
| NCT07391267 | NOT_YET_RECRUITING | Chronic Kidney Diseases; MAFLD |
Institute of Liver and Biliary Sciences, India |
2026-02-01 | |
| NCT06946628 | NOT_YET_RECRUITING | Diabetes Mellitus |
Sun Yat-sen University |
2025-06-01 | PHASE3 |
| NCT07275697 | RECRUITING | Atrial Fibrillation (AF); Obesity & Overweight |
Emma Svennberg |
2026-03-23 | PHASE4 |
| NCT07592546 | NOT_YET_RECRUITING | Class I/II Obesity |
Alain Dagher |
2026-08-01 | PHASE4 |
| NCT07581145 | RECRUITING | Foot Ulcer Due to Type 2 Diabetes Mellitus |
Ole Lander Svendsen |
2026-04-24 | PHASE3 |
| NCT06571383 | ACTIVE_NOT_RECRUITING | Obesity |
Novo Nordisk A/S |
2024-09-17 | PHASE4 |
| NCT07668414 | NOT_YET_RECRUITING | Overweight; Obesity |
Novo Nordisk A/S |
2026-09-22 | PHASE3 |
| NCT07589322 | RECRUITING | Obesity and Metabolic Syndrome |
Tri-Service General Hospital (TSGH) |
2026-03-31 | |
| NCT07743983 | RECRUITING | Type 2 Diabetes (T2DM) |
BrightGene Bio-Medical Technology Co., Ltd. |
2026-08-30 | PHASE3 |
| NCT07770152 | NOT_YET_RECRUITING | Autism Spectrum Disorder; Obesity |
Children's Hospital Medical Center, Cincinnati |
2026-09-01 | PHASE4 |
| NCT07617155 | NOT_YET_RECRUITING | Hypertriglyceridemia Induced Acute Pancreatitis; Recurrent Acute Pancreatitis; Pancreatitis Relapsing; Hypertriglyceridemia |
Peking Union Medical College Hospital |
2026-09 | PHASE4 |
| NCT07294950 | RECRUITING | Obesity (Disorder); Weight Change; Blood Pressure Monitoring; Appetite Regulation |
Mount Sinai Hospital, Canada |
2026-02-01 | PHASE3 |
| NCT05441267 | ACTIVE_NOT_RECRUITING | Diabetes Mellitus, Type 2 |
University of Oxford |
2023-03-13 | PHASE4 |
| NCT07091500 | RECRUITING | Obesity; Skeletal Muscle; Brain Connectivity |
Washington University School of Medicine |
2025-08-11 | |
| NCT07046273 | NOT_YET_RECRUITING | Type 2 Diabetes (T2DM) |
Shandong New Time Pharmaceutical Co., LTD |
2025-08-01 | PHASE3 |
| NCT05305794 | RECRUITING | Double Diabetes |
Centre Hospitalier Universitaire Dijon |
2022-07-12 | PHASE3 |
| NCT07065383 | RECRUITING | Diabetes Mellitus Type 2 |
University of Aberdeen |
2025-08-01 | |
| NCT07478653 | NOT_YET_RECRUITING | Obesity; Dental Care for Children |
Oelisoa Andriankaja |
2026-09-01 | |
| NCT07073053 | NOT_YET_RECRUITING | Glucagon-Like Peptide-1 Receptor Agonists; Type 2 Diabetes; Coronary Arterial Disease (CAD) |
Taipei Veterans General Hospital, Taiwan |
2025-10-01 | PHASE4 |
| NCT07249554 | NOT_YET_RECRUITING | Alcohol Use Disorder |
Johns Hopkins University |
2026-09 | PHASE2 |
| NCT07627191 | NOT_YET_RECRUITING | Pancreatic Cancer; Colorectal Cancer; Hepatocellular Carcinoma |
University of Arizona |
2026-07-10 | EARLY_PHASE1 |
| NCT07613437 | NOT_YET_RECRUITING | Intracerebral Hemorrhage |
Chinese University of Hong Kong |
2026-06-15 | PHASE2 |
| NCT07239570 | RECRUITING | Chronic Kidney Disease(CKD) |
Peter Rossing |
2025-06-20 | PHASE4 |
| NCT07325500 | RECRUITING | Weight Gain |
The University of Texas Health Science Center, Houston |
2026-02-12 | PHASE2 |
| NCT06986993 | RECRUITING | Tobacco Use |
University of Oklahoma |
2024-07-01 | PHASE4 |
| NCT07662213 | RECRUITING | Type 2 Diabetes Mellitus |
AstraZeneca |
2026-07-06 | PHASE3 |
| NCT07010432 | RECRUITING | Obesity |
Novo Nordisk A/S |
2025-06-12 | PHASE1 |
| NCT07563699 | RECRUITING | Diabete Type 2 |
Mapi Pharma Ltd. |
2026-08-09 | PHASE1; PHASE2 |
| NCT07727473 | NOT_YET_RECRUITING | Prostate Cancer |
Banner Health |
2026-07 | EARLY_PHASE1 |
| NCT06411210 | RECRUITING | Diabetes type1; Obesity |
Yale University |
2024-07-16 | PHASE2 |
| NCT07523633 | RECRUITING | Cannabis Use Disorder; Cannabis Use Disorders; Cannabis Abuse; Cannabis Dependence; Cannabis Addiction |
Anders Fink-Jensen, MD, DMSci |
2026-04-30 | PHASE2 |
| NCT07527195 | RECRUITING | Obesity |
Novo Nordisk A/S |
2026-04-10 | PHASE1 |
| NCT07284979 | RECRUITING | Obesity |
Kailera |
2025-12-30 | PHASE3 |
| NCT07653477 | NOT_YET_RECRUITING | Type 2 Diabetes |
The United Bio-Technology (Hengqin) Co., Ltd. |
2026-07-30 | PHASE3 |
| NCT07732426 | RECRUITING | Food Addiction Tendency; Obesity; Overweight |
Seoul National University Hospital |
2026-07-15 | |
| NCT07564414 | RECRUITING | Obesity; Type 2 Diabetes |
Novo Nordisk A/S |
2026-05-21 | PHASE3 |
| NCT07770841 | RECRUITING | Overweight; Obesity |
Novo Nordisk A/S |
2026-08-12 | PHASE3 |
| NCT05819853 | RECRUITING | PCOS (Polycystic Ovary Syndrome) of Bilateral Ovaries; Obese |
University of Colorado, Denver |
2023-11-03 | PHASE3 |
| NCT07213466 | RECRUITING | Bipolar I Disorder; Bipolar II Disorder; Schizo Affective Disorder; Obesity; Weight Loss; GLP - 1 |
Mayo Clinic |
2026-01-19 | PHASE4 |
| NCT07621640 | NOT_YET_RECRUITING | Obesity; Metabolic Syndrome; Brown Adipose Tissue |
Hallym University |
2026-06 | |
| NCT06801015 | ACTIVE_NOT_RECRUITING | Obesity |
Mayo Clinic |
2025-10-01 | PHASE4 |
| NCT07614412 | NOT_YET_RECRUITING | Type 1 Diabetes Mellitus |
Ministry of Health, Saudi Arabia |
2027-01-01 | PHASE2 |
| NCT07779343 | RECRUITING | Obesity Difficult Airway Airway Management; Obesity Adult Onset; Obesity and Cardiovascular Risk; Obesity Type 2 Diabetes Mellitus |
University of Health Sciences, Algeria |
2026-01-22 | |
| NCT07713992 | NOT_YET_RECRUITING | Type 2 Diabetes Mellitus (T2DM); Nonalcoholic Fatty Liver Disease (NAFLD) With History of Diabetes Melitus |
Tianjin Medical University |
2026-09-15 | |
| NCT07200622 | NOT_YET_RECRUITING | Alzheimer Disease |
Imperial College London |
2025-09-25 | PHASE2 |
| NCT07783854 | NOT_YET_RECRUITING | Obesity & Overweight |
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology |
2026-09-01 | PHASE4 |
| NCT05746039 | RECRUITING | Obesity; Interstitial Lung Disease; Chronic Obstructive Pulmonary Disease; Sarcoidosis, Pulmonary; Pulmonary Hypertension |
University of Pennsylvania |
2024-01-29 | PHASE1; PHASE2 |
| NCT06072963 | RECRUITING | Alzheimer Disease; Mild Cognitive Impairment; Metabolic Syndrome |
Rutgers, The State University of New Jersey |
2024-01-30 | PHASE2 |
| NCT06814938 | ACTIVE_NOT_RECRUITING | Obesity |
Mayo Clinic |
2025-02-21 | PHASE4 |
| NCT07622810 | NOT_YET_RECRUITING | Obesity & Overweight |
Carnot Laboratories |
2026-09 | PHASE3 |
| NCT06499857 | RECRUITING | Overweight or Obesity; Atrial Fibrillation |
University of Chicago |
2025-04-14 | PHASE3 |
| NCT05702931 | RECRUITING | Hyperglycemia; Renal Transplant Complication Primary Non-Function; Diabetes |
Rigshospitalet, Denmark |
2024-09-19 | PHASE4 |
| NCT06913023 | NOT_YET_RECRUITING | Kidney Transplant Recipient |
University Health Network, Toronto |
2026-01-05 | PHASE2; PHASE3 |
| NCT03811561 | ACTIVE_NOT_RECRUITING | Diabetes Mellitus, Type 2 |
Novo Nordisk A/S |
2019-05-08 | PHASE3 |
| NCT07184086 | RECRUITING | Obesity |
Novo Nordisk A/S |
2025-09-26 | PHASE1 |
| NCT07668388 | RECRUITING | Diabetes Mellitus, Type 2 |
Novo Nordisk A/S |
2026-06-22 | PHASE2 |
| NCT05938712 | RECRUITING | Kidney Transplant Recipients |
University Health Network, Toronto |
2023-10-24 | PHASE2 |
| NCT07628985 | NOT_YET_RECRUITING | Type 2 Diabetes Mellitus (T2DM) |
Carnot Laboratories |
2026-09 | PHASE3 |
| NCT07446998 | ACTIVE_NOT_RECRUITING | Obesity & Overweight; Mobility Disability; HOMA-IR |
Veru Inc. |
2026-03-26 | PHASE2 |
| NCT05669755 | ACTIVE_NOT_RECRUITING | Cardiovascular Disease |
Novo Nordisk A/S |
2023-03-01 | PHASE3 |
| NCT07136714 | RECRUITING | Major Depressive Disorder |
Nordsjaellands Hospital |
2025-09-11 | PHASE4 |
| NCT06042153 | ACTIVE_NOT_RECRUITING | Type 2 Diabetes; End Stage Renal Disease on Dialysis |
University of Texas Southwestern Medical Center |
2023-12-05 | PHASE4 |
| NCT06613854 | RECRUITING | Type 2 Diabetes Mellitus (T2DM) |
University Medical Centre Ljubljana |
2024-10-01 | PHASE4 |
| NCT07030621 | NOT_YET_RECRUITING | Acute Ischemic Stroke |
RenJi Hospital |
2025-07-01 | PHASE3 |
| NCT07639021 | RECRUITING | Obesity |
Novo Nordisk A/S |
2026-06-09 | PHASE2 |
| NCT06803888 | ACTIVE_NOT_RECRUITING | Obesity and Obesity-related Medical Conditions |
Ali Aminian |
2025-01-29 | PHASE4 |
| NCT07040592 | RECRUITING | Alcohol Use Disorder (AUD); HIV |
Yale University |
2026-01-15 | PHASE2 |
| NCT07150975 | RECRUITING | Obesity/Overweight in Adult |
Gan & Lee Pharmaceuticals. |
2025-09-23 | PHASE3 |
| NCT06318442 | RECRUITING | Steroid-Induced Diabetes; Steroid Induced Hyperglycemia |
Imperial College London |
2024-05-15 | |
| NCT07411378 | NOT_YET_RECRUITING | Muscle Wasting; Obesity & Overweight; Obesity |
Biophytis |
2026-07 | PHASE2 |
| NCT07317115 | RECRUITING | Obesity (Disorder); Obesity & Overweight; Type 2 Diabetes (T2DM) |
GT Metabolic Solutions, Inc. |
2026-03-18 | |
| NCT05822609 | RECRUITING | Diabetic Kidney Disease; Type 1 Diabetes |
University of Washington |
2024-04-05 | PHASE2 |
| NCT06003153 | RECRUITING | Genetic Predisposition; Metabolic Diseases; Type 2 Diabetes |
Massachusetts General Hospital |
2024-03-12 | PHASE4 |
| NCT07597018 | RECRUITING | Obesity; Overweight |
Novo Nordisk A/S |
2026-05-18 | PHASE1 |
| NCT07745504 | RECRUITING | Overweight; Obesity |
Novo Nordisk A/S |
2026-08-04 | PHASE3 |
| NCT06548490 | RECRUITING | Opioid Use Disorder; Opioid Abuse and Addiction; Narcotic-Related Disorders; Substance-Related Disorders; Chemically-Induced Disorders; Mental Disorder; Opioid |
Milton S. Hershey Medical Center |
2025-01-27 | PHASE2 |
| NCT05586802 | RECRUITING | Klinefelter Syndrome |
Georgios Papadakis |
2023-03-21 | PHASE3 |
| NCT05071898 | RECRUITING | Obesity; Diabetes Type 2 |
University of Maryland, Baltimore |
2022-04-11 | PHASE1 |
| NCT07293325 | RECRUITING | Adults With Simple Obesity |
Second Affiliated Hospital, Zhejiang University, School of Medicine |
2025-06-02 | |
| NCT06836284 | RECRUITING | Childhood Obesity; Treatment Adherence |
Karolinska Institutet |
2026-02-13 | |
| NCT06015893 | ACTIVE_NOT_RECRUITING | Addiction; Alcohol Use Disorder |
National Institute on Drug Abuse (NIDA) |
2023-10-17 | PHASE2 |
| NCT07314684 | RECRUITING | T2DM (Type 2 Diabetes Mellitus) |
Federico II University |
2025-09-08 | PHASE4 |
| NCT07011667 | ACTIVE_NOT_RECRUITING | Obesity |
Novo Nordisk A/S |
2025-06-03 | PHASE3 |
| NCT07101939 | RECRUITING | Obesity; Muscle Loss |
Actimed Therapeutics Ltd |
2025-06-23 | PHASE2 |
| NCT07801820 | RECRUITING | Type 2 Diabetes Mellitus (T2DM) |
Shanghai Minwei Biotechnology Co., Ltd |
2026-06-23 | PHASE2 |
| NCT07285902 | ACTIVE_NOT_RECRUITING | Obesity |
Fujian Shengdi Pharmaceutical Co., Ltd. |
2025-12-25 | PHASE3 |
| NCT06338553 | RECRUITING | Type 1 Diabetes |
Vanderbilt University Medical Center |
2024-06-12 | EARLY_PHASE1 |
| NCT07401992 | RECRUITING | Psoriasis (PsO); Obesity & Overweight; Diabetes Mellitus - Type 2 |
Hospital Universitario Dr. Jose E. Gonzalez |
2026-01-15 | PHASE4 |
| NCT07073417 | ACTIVE_NOT_RECRUITING | Obesity; Weight Management |
Hangzhou Sciwind Biosciences Co., Ltd. |
2025-07-28 | PHASE2 |
| NCT07673900 | RECRUITING | Overweight and/or Obesity |
Terrestrial Bio, Inc. |
2026-06-15 | PHASE1 |
| NCT07282769 | NOT_YET_RECRUITING | Trichotillomania (Hair-Pulling Disorder); Trichotillomania; Hair Pulling Disorder; Hair Pulling; Hair-Pulling Disorder |
University of Chicago |
2026-06 | PHASE2 |
| NCT07242534 | RECRUITING | Infertility; Obesity |
Fundacion Dexeus |
2026-01-19 | PHASE4 |
| NCT07599046 | NOT_YET_RECRUITING | Obesity Type 2 Diabetes Mellitus |
Eighth Affiliated Hospital, Sun Yat-sen University |
2026-04-30 | |
| NCT05202353 | ACTIVE_NOT_RECRUITING | Obesity |
Boehringer Ingelheim |
2024-11-01 | PHASE1 |
| NCT07251556 | NOT_YET_RECRUITING | Psoriasis Arthritis |
Chinese University of Hong Kong |
2025-12-01 | PHASE4 |
| NCT07509112 | NOT_YET_RECRUITING | Methamphetamine Use Disorder |
Kirby Institute |
2026-09 | PHASE2 |
| NCT06387199 | RECRUITING | Type 1 Diabetes; Diabetes Mellitus |
McGill University Health Centre/Research Institute of the McGill University Health Centre |
2024-12-01 | PHASE2; PHASE3 |
| NCT04174755 | RECRUITING | Obesity; HIV-1-infection |
University College Dublin |
2022-06-22 | |
| NCT06894784 | RECRUITING | Diabetes Type 1 |
McGill University Health Centre/Research Institute of the McGill University Health Centre |
2025-04 | PHASE3 |
| NCT07297589 | RECRUITING | STEMI - ST Elevation Myocardial Infarction; Epicardial Fat |
Instituto Mexicano del Seguro Social |
2025-12-30 | PHASE3 |
| NCT06461377 | RECRUITING | Type 2 Diabetes; Diabetes With Diabetic Autonomic Neuropathy (Diagnosis) |
The First Affiliated Hospital with Nanjing Medical University |
2024-06-13 | PHASE4 |
| NCT06825793 | NOT_YET_RECRUITING | Obesity |
Beijing Chao Yang Hospital |
2025-02-20 | |
| NCT06449625 | NOT_YET_RECRUITING | Intestinal Mucositis; Inflammation; Chemotherapeutic Toxicity |
Klaus Gottlob Müller |
2024-08-12 | PHASE2 |
| NCT06884293 | ACTIVE_NOT_RECRUITING | Overweight; Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD) |
Innovent Biologics (Suzhou) Co. Ltd. |
2025-05-09 | PHASE3 |
| NCT07057310 | ENROLLING_BY_INVITATION | Obesity; Menopause |
Mayo Clinic |
2025-05-01 | PHASE4 |
| NCT06989203 | RECRUITING | Obesity; Weight Loss; Protein Supplementation |
Chinese Academy of Sciences |
2025-06-10 | |
| NCT06959784 | ENROLLING_BY_INVITATION | Diabetes Mellitus; Cardiovascular Diseases; Cerebrovascular Disease |
China-Japan Friendship Hospital |
2024-01-01 | PHASE4 |
| NCT06546384 | NOT_YET_RECRUITING | Adiposity; Fatty Liver; Alcohol Use Disorder |
Insel Gruppe AG, University Hospital Bern |
2026-11-01 | |
| NCT05173714 | RECRUITING | Chronic Kidney Diseases; Obesity |
Srinvasan Beddhu |
2021-12-01 | PHASE2 |
| NCT06989177 | RECRUITING | Obesity; Homeostasis; Weight Loss; Probiotic Intervention |
Chinese Academy of Sciences |
2025-06-10 | |
| NCT07225816 | RECRUITING | Obesity |
Novo Nordisk A/S |
2025-11-07 | PHASE1 |
| NCT06778967 | ACTIVE_NOT_RECRUITING | Type 2 Diabetes Mellitus (T2DM) |
Gan & Lee Pharmaceuticals. |
2025-02-13 | PHASE3 |
| NCT07139548 | NOT_YET_RECRUITING | T2DM |
Guangdong Raynovent Biotech Co., Ltd |
2025-08-31 | PHASE3 |
| NCT06897475 | RECRUITING | Type 2 Diabetes |
Eli Lilly and Company |
2025-03-28 | PHASE2 |
| NCT06982859 | ACTIVE_NOT_RECRUITING | Diabetes Mellitus; Insulin Sensitivity |
Eli Lilly and Company |
2025-06-02 | PHASE1 |
| NCT07430059 | NOT_YET_RECRUITING | Obesity & Overweight |
Vivani Medical, Inc |
2026-07 | PHASE1 |
| NCT07570810 | NOT_YET_RECRUITING | Type 2 Diabetes; Obesity; Non-alcoholic Fatty Liver Disease |
Shanghai Jiao Tong University School of Medicine |
2026-06-01 | |
| NCT07112872 | ACTIVE_NOT_RECRUITING | Type 2 Diabetes Mellitus |
Hoffmann-La Roche |
2025-08-19 | PHASE2 |
| NCT06577090 | ACTIVE_NOT_RECRUITING | Obesity |
Skye Bioscience, Inc. |
2024-08-22 | PHASE2 |
| NCT05119179 | RECRUITING | PreDiabetes |
The University of Texas Health Science Center, Houston |
2021-11-22 | PHASE4 |
| NCT07223983 | RECRUITING | Alcohol Use Disorder; Weight Loss; Bariatric Surgery Patients |
Yale University |
2026-03-06 | PHASE1 |
| NCT07505303 | ACTIVE_NOT_RECRUITING | Adult Obesity; Weight Management |
Eccogene |
2026-03-23 | PHASE2 |
| NCT07319975 | NOT_YET_RECRUITING | Obesity |
Istanbul Galata University |
2025-12-29 | |
| NCT06396416 | RECRUITING | Obesity; Chronic Kidney Disease |
Western University, Canada |
2024-09-26 | PHASE4 |
| NCT07087795 | ACTIVE_NOT_RECRUITING | Diabetes Mellitus, Type 1 |
Novo Nordisk A/S |
2025-07-01 | PHASE1 |
| NCT06717698 | RECRUITING | Chronic Kidney Disease |
Novo Nordisk A/S |
2024-12-02 | PHASE2 |
| NCT05501483 | RECRUITING | Type 2 Diabetes |
Karolinska Institutet |
2023-02-08 | |
| NCT07187856 | NOT_YET_RECRUITING | Type 2 Diabetes Mellitus (T2DM) |
ProGen. Co., Ltd. |
2026-01 | PHASE2 |
| NCT05254314 | ACTIVE_NOT_RECRUITING | Asthma |
Vanderbilt University Medical Center |
2022-10-11 | PHASE2 |
| NCT06639464 | RECRUITING | Opioid Use Disorder |
Brigham and Women's Hospital |
2025-06-02 | PHASE2 |
| NCT07513168 | RECRUITING | Obesity; Weight Reduction; Cardiometabolic Risk Factors |
Asian Institute Of Medical Sciences |
2025-08-01 | PHASE4 |
| NCT07220629 | ACTIVE_NOT_RECRUITING | Obesity |
NodThera Limited |
2025-10-02 | PHASE2 |
| NCT06797869 | ACTIVE_NOT_RECRUITING | Diabetes Mellitus, Type 2; Diabetic Peripheral Neuropathy |
Novo Nordisk A/S |
2025-01-29 | PHASE2 |
| NCT07465965 | RECRUITING | Overweight; Obesity |
Shanghai World Leader Pharmaceutical Co., Ltd. |
2026-03-02 | PHASE1 |
| NCT07179120 | NOT_YET_RECRUITING | Obesity-related Male Infertility |
First Affiliated Hospital of Wenzhou Medical University |
2026-05-01 | PHASE2 |
| NCT05424003 | RECRUITING | NAFLD |
University of Virginia |
2024-02-22 | PHASE2 |
| NCT06260722 | ACTIVE_NOT_RECRUITING | Diabetes Mellitus, Type 2 |
Eli Lilly and Company |
2024-02-21 | PHASE3 |
| NCT07064486 | RECRUITING | Type 2 Diabetes (T2DM) |
BrightGene Bio-Medical Technology Co., Ltd. |
2025-07-04 | PHASE3 |
| NCT06937060 | RECRUITING | Psoriasis (PsO); Obesity and Overweight |
The University of Hong Kong |
2025-03-20 | PHASE3 |
| NCT06649344 | COMPLETED | Type 2 Diabetes |
Fujian Shengdi Pharmaceutical Co., Ltd. |
2024-10-31 | PHASE3 |
| NCT05371496 | COMPLETED | Cardiomyopathy; Heart Failure With Preserved Ejection Fraction (HFpEF); Obesity |
Mayo Clinic |
2022-09-06 | PHASE4 |
| NCT07059377 | RECRUITING | Diabetes Mellitus, Type 2; Nicotine Addiction; Tobacco Dependence |
Ottawa Heart Institute Research Corporation |
2026-02-13 | PHASE3 |
| NCT06851962 | COMPLETED | Diabetes Mellitus Type 2 |
Fundación para la Investigación del Hospital Clínico de Valencia |
2025-05-26 | PHASE4 |
| NCT07272343 | RECRUITING | Type 2 Diabetes Mellitus (T2DM); Semaglutide; Caloric Restriction |
Second Affiliated Hospital of Nanchang University |
2023-02-10 | PHASE4 |
| NCT07271251 | COMPLETED | Type 2 Diabetes |
Novo Nordisk A/S |
2025-12-01 | PHASE3 |
| NCT07554417 | NOT_YET_RECRUITING | GLP - 1; Obesity & Overweight; Muscle Loss; Exercise Intervention; Dietary Assessment |
William Marsh Rice University |
2026-04-06 | PHASE4 |
| NCT06534411 | COMPLETED | Diabetes Mellitus, Type 2 |
Novo Nordisk A/S |
2024-11-05 | PHASE3 |
| NCT07374328 | RECRUITING | Type 2 Diabetes |
Second Affiliated Hospital of Guangzhou Medical University |
2025-06-01 | PHASE1; PHASE2 |
| NCT06633783 | NOT_YET_RECRUITING | Obesity |
Hangzhou Jiuyuan Gene Engineering Co. Ltd., |
2024-10-30 | PHASE3 |
| NCT06184633 | RECRUITING | Atrial Fibrillation; Obesity; Weight Loss |
Rijnstate Hospital |
2024-07-21 | PHASE4 |
| NCT06764056 | NOT_YET_RECRUITING | Metabolic Associated Fatty Liver Disease; Metabolic Associated-dysfunction Steatohepatitis (MASH); Obesity |
Institut universitaire de cardiologie et de pneumologie de Québec, University Laval |
2025-01 | |
| NCT07610174 | COMPLETED | Heart Failure; Heart Valve Prosthesis |
Kafrelsheikh University |
2025-06-02 | PHASE2 |
| NCT05574439 | COMPLETED | Obesity, Adolescent |
Signe Torekov |
2022-05-30 | PHASE4 |
| NCT07254715 | RECRUITING | Semaglutide-Induced Gastric Motility; Anesthesia |
Ain Shams University |
2025-12 | PHASE4 |
| NCT05780905 | RECRUITING | Diabetes Mellitus, Type 2; Stroke (CVA) or Transient Ischemic Attack |
University of Washington |
2024-01-11 | PHASE4 |
| NCT06716216 | RECRUITING | Type 2 Diabetes Mellitus (T2DM) |
BrightGene Bio-Medical Technology Co., Ltd. |
2024-11-29 | PHASE3 |
| NCT06221969 | COMPLETED | Type 2 Diabetes |
Novo Nordisk A/S |
2024-01-16 | PHASE3 |
| NCT06827002 | ACTIVE_NOT_RECRUITING | Obesity and Overweight; Appetite Regulation |
University of Yaounde 1 |
2023-03-29 | PHASE1; PHASE2 |
| NCT06605703 | COMPLETED | Obesity; Overweight |
WW International Inc |
2024-09-18 | PHASE4 |
| NCT03899402 | ACTIVE_NOT_RECRUITING | Type 1 Diabetes Mellitus |
State University of New York at Buffalo |
2019-05-01 | PHASE2; PHASE3 |
| NCT05340868 | RECRUITING | PreDiabetes; Prediabetic State; Obesity |
Medical University of Bialystok |
2022-09-01 | |
| NCT05877547 | COMPLETED | Non-alcoholic Fatty Liver Disease; Fatty Liver, Nonalcoholic; NAFLD; Nonalcoholic Fatty Liver Disease; Nonalcoholic Steatohepatitis |
Merck Sharp & Dohme LLC |
2023-06-23 | PHASE2 |
| NCT06403761 | COMPLETED | Diabetes Mellitus, Type 2 |
Novo Nordisk A/S |
2024-05-06 | PHASE1 |
| NCT06579105 | COMPLETED | Diabetes Mellitus, Type 2 |
AstraZeneca |
2024-10-08 | PHASE2 |
| NCT07171723 | RECRUITING | Obesity &Amp; Overweight |
University Hospital, Gentofte, Copenhagen |
2025-09-01 | PHASE1; PHASE2 |
| NCT06131437 | COMPLETED | Obesity |
Novo Nordisk A/S |
2023-11-27 | PHASE3 |
| NCT06409130 | COMPLETED | Alcohol-related Liver Disease |
Novo Nordisk A/S |
2024-05-20 | PHASE2 |
| NCT07163624 | COMPLETED | Type 2 Diabetes Mellitus (T2DM) |
The United Bio-Technology (Hengqin) Co., Ltd. |
2025-03-22 | PHASE2 |
| NCT06065540 | COMPLETED | Type 2 Diabetes Mellitus |
Novo Nordisk A/S |
2023-09-27 | PHASE3 |
| NCT05892432 | COMPLETED | Alcohol Use Disorder |
University of Colorado, Denver |
2024-01-11 | PHASE2 |
| NCT06363747 | ACTIVE_NOT_RECRUITING | Type 2 Diabetes; Obesity |
Durham VA Medical Center |
2024-06-24 | PHASE2; PHASE3 |
| NCT06608433 | COMPLETED | Healthy Volunteer Study; HPA; Cortisol Deficiency; Adrenal Insufficiency |
University Hospital, Basel, Switzerland |
2025-01-16 | |
| NCT07280403 | COMPLETED | Weight Loss |
INQUIS Clinical Research |
2024-09-12 | |
| NCT06323174 | COMPLETED | Type 2 Diabetes |
Novo Nordisk A/S |
2024-03-19 | PHASE3 |
| NCT05646199 | UNKNOWN | Polycystic Ovary Syndrome |
University of Hull |
2025-03-01 | PHASE2; PHASE3 |
| NCT06972992 | COMPLETED | Chronic Weight Management |
Ascletis Pharma (China) Co., Limited |
2025-04-18 | PHASE1 |
| NCT06184568 | COMPLETED | Type 2 Diabetes; Obesity |
Innovent Biologics (Suzhou) Co. Ltd. |
2024-02-29 | PHASE3 |
| NCT04777409 | COMPLETED | Early Alzheimer´s Disease |
Novo Nordisk A/S |
2021-05-18 | PHASE3 |
| NCT04990024 | UNKNOWN | Obesity; Weight Loss |
American University of Beirut Medical Center |
2021-07-01 | |
| NCT06323161 | COMPLETED | Type 2 Diabetes |
Novo Nordisk A/S |
2024-03-26 | PHASE3 |
| NCT06060392 | RECRUITING | Liver Transplant; Complications; Diabete Mellitus |
Medanta, The Medicity, India |
2023-10-30 | |
| NCT05630586 | RECRUITING | Acute Ischemic Stroke |
Aarhus University Hospital |
2023-04-12 | PHASE2 |
| NCT06339086 | UNKNOWN | Type 2 Diabetes Mellitus |
Chengdu Brilliant Pharmaceutical Co., Ltd. |
2024-04 | PHASE3 |
| NCT06604624 | COMPLETED | Weight Management |
CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. |
2024-09-20 | PHASE3 |
| NCT06045221 | COMPLETED | Type 2 Diabetes |
Eli Lilly and Company |
2023-09-22 | PHASE3 |
| NCT04854083 | UNKNOWN | Type2 Diabetes |
Kirsi Pietiläinen |
2022-02-17 | PHASE4 |
| NCT05895643 | COMPLETED | Alcohol Abuse; Alcohol Addiction; Alcohol Dependence; Alcohol Use Disorder |
Psychiatric Centre Rigshospitalet |
2023-06-13 | PHASE2 |
| NCT06648031 | COMPLETED | Type2diabetes |
Lexaria Bioscience Corp. |
2024-12-04 | PHASE1 |
| NCT06541509 | UNKNOWN | Heart Failure; Obesity |
University Medical Centre Ljubljana |
2024-07-10 | PHASE1; PHASE2 |
| NCT06292065 | COMPLETED | Gastroparesis |
Nils Vlaeminck |
2024-04-16 | |
| NCT06161844 | COMPLETED | Type 2 Diabetes Mellitus |
CSPC ZhongQi Pharmaceutical Technology Co., Ltd. |
2024-02-23 | PHASE3 |
| NCT04596631 | COMPLETED | Diabetes Mellitus, Type 2 |
Novo Nordisk A/S |
2020-11-02 | PHASE3 |
| NCT05813912 | COMPLETED | Diabetes Mellitus, Type 2 |
Novo Nordisk A/S |
2023-09-22 | PHASE3 |
| NCT06267092 | COMPLETED | Overweight; Obesity |
Novo Nordisk A/S |
2024-02-15 | PHASE1 |
| NCT06041217 | COMPLETED | Overweight; Obesity |
Novo Nordisk A/S |
2023-09-15 | PHASE3 |
| NCT06619015 | WITHDRAWN | Obesity; Appetite Regulation; PreDiabetes |
Esbjerg Hospital - University Hospital of Southern Denmark |
2025-04-01 | PHASE2; PHASE3 |
| NCT06716307 | COMPLETED | Obesity |
Novo Nordisk A/S |
2024-12-02 | PHASE1 |
| NCT05984238 | COMPLETED | Diabetes Mellitus, Type 2 |
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) |
2023-08-03 | |
| NCT06555146 | UNKNOWN | Diabetes Mellitus, Type 2; Kidney Disease, Chronic |
Bispebjerg Hospital |
2024-08 | |
| NCT05073835 | ACTIVE_NOT_RECRUITING | Obesity; Diabetes; Metabolic Syndrome |
University College, London |
2022-11-01 | PHASE3 |
| NCT06492330 | COMPLETED | Metabolic Dysfunction-Associated Steatohepatitis (MASH); Obesity; Diabetes Mellitus, Type 2 |
Shanghai Jiao Tong University School of Medicine |
2024-07-19 | |
| NCT05779644 | UNKNOWN | Metformin; Obesity, Abdominal; Diabetes Mellitus, Type 2; Abdominal Fat; Non-Alcoholic Fatty Liver Disease; Metabolism Disorder, Glucose; Metabolism Disorder, Lipid |
RenJi Hospital |
2023-02-23 | |
| NCT04639414 | COMPLETED | Type 2 Diabetes; Non-alcoholic Steatohepatitis (NASH); Non-alcoholic Fatty Liver Disease (NAFLD) |
German Diabetes Center |
2021-03-26 | PHASE4 |
| NCT06027567 | COMPLETED | Idiopathic Intracranial Hypertension; Intracranial Pressure; Obesity; Pseudotumor Cerebri Syndrome; Papilledema; Weight Loss |
Rigmor Højland Jensen |
2022-09-02 | PHASE4 |
| NCT05394519 | COMPLETED | Overweight; Obesity; Type 2 Diabetes Mellitus |
Novo Nordisk A/S |
2023-02-01 | PHASE3 |
| NCT06083675 | WITHDRAWN | Diabetes Mellitus, Type 2 |
Novo Nordisk A/S |
2024-01-26 | PHASE3 |
| NCT05813925 | COMPLETED | Obesity or Overweight |
Novo Nordisk A/S |
2023-04-03 | PHASE3 |
| NCT05890976 | COMPLETED | Overweight; Obesity |
Novo Nordisk A/S |
2023-05-30 | PHASE3 |
| NCT05078255 | COMPLETED | Type 2 Diabetes; Obesity |
Asger Lund, MD |
2022-01-27 | |
| NCT05996848 | COMPLETED | Obesity or Overweight |
Novo Nordisk A/S |
2023-08-15 | PHASE3 |
| NCT06640972 | COMPLETED | Triglycerides; Weight Gain Trajectory; Cholesterol, Elevated |
Response Pharmaceuticals |
2024-09-27 | PHASE2 |
| NCT06243536 | UNKNOWN | Type 2 Diabetes; Overweight; Disordered Eating Behaviors |
University Hospital Sestre Milosrdnice |
2024-02-01 | PHASE4 |
| NCT06057077 | UNKNOWN | Type 1 Diabetes |
Ministry of Health, Saudi Arabia |
2024-01-01 | PHASE1; PHASE2 |
| NCT04466345 | COMPLETED | Major Depressive Disorder |
University Health Network, Toronto |
2021-10-06 | PHASE2 |
| NCT06400615 | COMPLETED | OSA |
Apnimed |
2024-05-20 | PHASE2 |
| NCT05788965 | COMPLETED | Cystic Fibrosis; Cystic Fibrosis-related Diabetes |
University of Minnesota |
2023-10-16 | PHASE2; PHASE3 |
| NCT05016882 | COMPLETED | Non-alcoholic Steatohepatitis |
Novo Nordisk A/S |
2021-08-31 | PHASE2 |
| NCT06361823 | UNKNOWN | Idiopathic Intracranial Hypertension |
Capital Medical University |
2024-05-01 | PHASE3 |
| NCT05714683 | Not yet recruiting | Diabetes Mellitus Type 2 |
Novo Nordisk A/S |
2024-12-31 | -- |
| NCT05071417 | UNKNOWN | Atheroscleroses, Coronary |
Fundación Instituto de Estudios de Ciencias de la Salud de Castilla y León |
2021-11 | PHASE3 |
| NCT05870462 | UNKNOWN | Atherosclerosis; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Obesity |
Canadian Medical and Surgical Knowledge Translation Research Group |
2023-04-29 | PHASE4 |
| NCT05579249 | COMPLETED | Obesity |
Novo Nordisk A/S |
2023-01-19 | PHASE4 |
| NCT05950516 | UNKNOWN | Type 2 Diabetes |
Qilu Pharmaceutical Co., Ltd. |
2023-07-10 | PHASE3 |
| NCT04865770 | COMPLETED | Diabetes Mellitus, Type 2; Chronic Kidney Disease |
Novo Nordisk A/S |
2021-04-28 | PHASE3 |
| NCT04779697 | COMPLETED | Obesity |
Yale University |
2021-02-01 | PHASE1 |
| NCT06634927 | COMPLETED | Type 2 Diabetes |
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. |
2024-09-22 | PHASE1 |
| NCT05822830 | COMPLETED | Obesity; Overweight |
Eli Lilly and Company |
2023-04-21 | PHASE3 |
| NCT06422624 | UNKNOWN | Diabetes Mellitus, Type 2 |
Bostal Drug Delivery Co., Ltd |
2024-08 | PHASE1 |
| NCT05567796 | ACTIVE_NOT_RECRUITING | Obesity |
Novo Nordisk A/S |
2022-11-01 | PHASE3 |
| NCT05649137 | COMPLETED | Obesity; Diabetes Mellitus, Type 2 |
Novo Nordisk A/S |
2023-01-04 | PHASE3 |
| NCT05920889 | COMPLETED | Stroke; Stroke, Acute; Stroke, Ischemic; Brain Diseases |
Chinese University of Hong Kong |
2023-08-01 | PHASE2 |
| NCT04979130 | COMPLETED | Type 2 Diabetes; Chronic Inflammation; Intestinal Permeability |
University of Colorado, Denver |
2022-01-01 | PHASE4 |
| NCT06289504 | COMPLETED | Obesity |
Novo Nordisk A/S |
2024-02-27 | PHASE1 |
| NCT06739044 | COMPLETED | Type 2 Diabetes |
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. |
2023-09-20 | PHASE3 |
| NCT05444153 | WITHDRAWN | Diabetes Mellitus, Type 2 |
Novo Nordisk A/S |
2022-10-06 | PHASE3 |
| NCT05897372 | TERMINATED | Diabetic Kidney Disease |
Iain Bressendorff |
2023-08-01 | PHASE2 |
| NCT06500429 | COMPLETED | Overweight and Obesity; Healthy |
Neurogastrx, Inc. |
2024-06-24 | PHASE2 |
| NCT06557811 | UNKNOWN | Diabetic Patients; Acute Myocardial Infarction |
University of Sao Paulo General Hospital |
2024-09-01 | PHASE4 |
| NCT05891496 | COMPLETED | Alzheimers Disease |
Novo Nordisk A/S |
2023-06-20 | PHASE3 |
| NCT06974825 | COMPLETED | Type 2 Diabetes |
BrightGene Bio-Medical Technology Co., Ltd. |
2023-08-30 | PHASE2 |
| NCT05751226 | COMPLETED | Healthy; Obesity |
Boehringer Ingelheim |
2023-04-11 | PHASE1 |
| NCT06256549 | UNKNOWN | Type 2 Diabetes |
Gan and Lee Pharmaceuticals, USA |
2023-08-09 | PHASE2 |
| NCT05689372 | Not yet recruiting | Diabetes Mellitus Type 2 |
Novo Nordisk A/S |
2024-06-30 | -- |
| NCT05087342 | COMPLETED | Obesity; Obesity; Drug; Overweight or Obesity; Weight Loss; Weight Loss Trajectory; Weight, Body |
Loma Linda University |
2022-12-13 | PHASE3 |
| NCT04889183 | COMPLETED | Obesity; Albuminuria |
University Medical Center Groningen |
2022-03-14 | PHASE3 |
| NCT06699329 | COMPLETED | Healthy |
Merck Sharp & Dohme LLC |
2024-01-22 | PHASE1 |
| NCT05786521 | COMPLETED | Aging; Diabetes Mellitus, Type 2; PreDiabetes; Overweight and Obesity |
The University of Texas Health Science Center at San Antonio |
2023-04-01 | PHASE4 |
| NCT05616013 | COMPLETED | Obesity; Obese; Overweight or Obesity |
Eli Lilly and Company |
2022-11-16 | PHASE2 |
| NCT05530577 | COMPLETED | Tobacco Use Disorder; Nicotine Addiction |
University of North Carolina, Chapel Hill |
2022-10-07 | PHASE2 |
| NCT06015893 | Recruiting | Addiction|Alcohol Use Disorder |
National Institute on Drug Abuse (NIDA)|National Institutes of Health Clinical Center (CC) |
2024-05-15 | Phase 2 |
| NCT04019197 | ACTIVE_NOT_RECRUITING | HIV/AIDS; Lipohypertrophy; Obesity |
Case Western Reserve University |
2019-05-16 | PHASE2 |
| NCT05322200 | UNKNOWN | Diabetes Mellitus; Acute Coronary Syndrome; Coronary Artery Disease |
Swansea Bay University Health Board |
2022-08-31 | PHASE4 |
| NCT05564117 | COMPLETED | Overweight; Obesity |
Novo Nordisk A/S |
2022-10-11 | PHASE3 |
| NCT05996874 | COMPLETED | Healthy Participants |
Novo Nordisk A/S |
2023-08-12 | PHASE1 |
| NCT06629688 | COMPLETED | Diabetes Mellitus Type 2; Iron Absorption |
University Hospital Dubrava |
2023-11-01 | |
| NCT05193578 | COMPLETED | Schizophrenia; Prediabetic State |
Jan Frystyk |
2022-01-01 | PHASE2 |
| NCT06097390 | COMPLETED | Healthy Participants |
Novo Nordisk A/S |
2023-09-28 | PHASE1 |
| NCT05813249 | COMPLETED | Non-alcoholic Fatty Liver Disease |
Zagazig University |
2023-02-15 | PHASE4 |
| NCT05533632 | COMPLETED | Diabetes Mellitus, Type 2 |
Novo Nordisk A/S |
2022-04-25 | PHASE4 |
| NCT05766709 | COMPLETED | Non-alcoholic Steatohepatitis |
Novo Nordisk A/S |
2023-03-02 | PHASE1 |
| NCT05990374 | UNKNOWN | Diabetes |
Nanjing First Hospital, Nanjing Medical University |
2023-08-01 | |
| NCT05390307 | COMPLETED | Type 1 Diabetes |
Dasman Diabetes Institute |
2023-04-01 | |
| NCT05303857 | COMPLETED | Diabetes Mellitus, Type 2 |
University of Erlangen-Nürnberg Medical School |
2022-03-03 | PHASE4 |
| NCT05616052 | UNKNOWN | Weight Change, Body |
Huashan Hospital |
2022-12-01 | PHASE4 |
| NCT06221696 | COMPLETED | Overweight and Obesity |
S.LAB (SOLOWAYS) |
2023-06-12 | |
| NCT05671653 | TERMINATED | Obesity |
Pfizer |
2023-01-19 | PHASE1 |
| NCT04126603 | COMPLETED | Diabetes Mellitus, Type 2 |
Sabyasachi Sen |
2019-08-01 | PHASE4 |
| NCT05302596 | COMPLETED | Obesity; Aging |
State University of New York at Buffalo |
2022-09-01 | PHASE2 |
| NCT04998136 | COMPLETED | Obesity |
Novo Nordisk A/S |
2022-08-15 | PHASE3 |
| NCT05486065 | COMPLETED | Diabetes Mellitus, Type 2 |
Novo Nordisk A/S |
2022-08-08 | PHASE2 |
| NCT04916470 | COMPLETED | Heart Failure With Preserved Ejection Fraction (HFpEF) and Diabetes Mellitus, Type 2 |
Novo Nordisk A/S |
2021-06-15 | PHASE3 |
| NCT03919929 | COMPLETED | PCOS; Adolescent Obesity; NAFLD |
University of Colorado, Denver |
2019-05-03 | PHASE2; PHASE3 |
| NCT05478252 | COMPLETED | Diabetes Mellitus, Type 2 |
Novo Nordisk A/S |
2022-08-03 | PHASE3 |
| NCT05816057 | COMPLETED | Diabetes Mellitus, Type 2 |
Hangzhou Jiuyuan Gene Engineering Co. Ltd., |
2022-07-25 | PHASE3 |
| NCT05064735 | COMPLETED | Obesity |
Novo Nordisk A/S |
2021-10-01 | PHASE3 |
| NCT05579977 | TERMINATED | Diabetes Mellitus; Obesity |
Pfizer |
2022-10-27 | PHASE2 |
| NCT05132088 | COMPLETED | Overweight and Obesity |
Novo Nordisk A/S |
2021-11-16 | PHASE3 |
| NCT05442450 | UNKNOWN | Obesity; Weight Loss |
Asian Institute of Gastroenterology, India |
2022-07-10 | PHASE4 |
| NCT05227196 | COMPLETED | Healthy Volunteers; Type 2 Diabetes |
Novo Nordisk A/S |
2022-02-04 | PHASE1 |
| NCT06215196 | COMPLETED | Overweight and Obesity |
S.LAB (SOLOWAYS) |
2023-04-14 | |
| NCT03574597 | COMPLETED | Overweight; Obesity |
Novo Nordisk A/S |
2018-10-24 | PHASE3 |
| NCT05689099 | COMPLETED | Diabetes Mellitus, Type 2; Healthy Participants |
Novo Nordisk A/S |
2023-01-17 | PHASE1 |
| NCT06489457 | COMPLETED | Type 2 Diabetes Mellitus; Obesity; Functional Hypogonadism |
University Medical Centre Ljubljana |
2020-09-20 | PHASE3 |
| NCT05147896 | UNKNOWN | Diabetes Mellitus, Type 2; Atherosclerosis |
University Medical Centre Ljubljana |
2022-05-01 | |
| NCT04788511 | COMPLETED | Obesity |
Novo Nordisk A/S |
2021-03-16 | PHASE3 |
| NCT04216589 | COMPLETED | HIV Infections; Non-Alcoholic Fatty Liver Disease |
National Institute of Allergy and Infectious Diseases (NIAID) |
2021-02-19 | PHASE2 |
| NCT05429593 | COMPLETED | Healthy Volunteers |
Novo Nordisk A/S |
2022-06-22 | PHASE1 |
| NCT04707469 | COMPLETED | Diabetes Mellitus, Type 2 |
Novo Nordisk A/S |
2021-01-15 | PHASE3 |
| NCT05129891 | COMPLETED | Healthy Volunteers; High Blood Cholesterol Levels; Type 2 Diabetes |
Novo Nordisk A/S |
2021-11-03 | PHASE1 |
| NCT04938388 | TERMINATED | Diabetes Mellitus, Type 2; Glucose Metabolism Disorders (Including Diabetes Mellitus) |
Sansum Diabetes Research Institute |
2022-01-29 | PHASE4 |
| NCT05144984 | COMPLETED | Diabetes Mellitus, Type 2 |
Novo Nordisk A/S |
2021-11-29 | PHASE2 |
| NCT04741074 | TERMINATED | CKD; Diabetic Kidney Disease; Type 2 Diabetes Mellitus in Obese; Obesity; Severe Obesity |
Geisinger Clinic |
2021-07-23 | PHASE3 |
| NCT05040971 | COMPLETED | Obesity |
Novo Nordisk A/S |
2021-09-06 | PHASE3 |
| NCT04032197 | COMPLETED | Diabetes Mellitus, Type 2 |
Novo Nordisk A/S |
2019-08-12 | PHASE1 |
| NCT04969939 | COMPLETED | Obesity |
Novo Nordisk A/S |
2021-07-15 | PHASE2 |
| NCT05249881 | UNKNOWN | Diabetes Mellitus, Type 2; Weight Change, Body |
Aga Khan University |
2022-03-10 | EARLY_PHASE1 |
| NCT05498610 | COMPLETED | Diabetes Mellitus, Type 2 |
Novo Nordisk A/S |
2022-08-11 | PHASE1 |
| NCT05236517 | COMPLETED | Obesity |
Novo Nordisk A/S |
2022-02-08 | PHASE1 |
| NCT05232708 | COMPLETED | Healthy Volunteers (Diabetes Mellitus, Type 2) |
Novo Nordisk A/S |
2022-01-19 | PHASE1 |
| NCT04251156 | COMPLETED | Overweight; Obesity; Diabetes Mellitus, Type 2 |
Novo Nordisk A/S |
2020-12-08 | PHASE3 |
| NCT05153564 | COMPLETED | Diabetes Mellitus, Type 2 |
Novo Nordisk A/S |
2021-12-13 | PHASE1 |
| NCT04624672 | TERMINATED | Diabetes Mellitus, Type 2 |
Geisinger Clinic |
2021-08-25 | PHASE4 |
| NCT04982575 | COMPLETED | Diabetes Mellitus, Type 2 |
Novo Nordisk A/S |
2021-08-02 | PHASE2 |
| NCT03596450 | COMPLETED | Diabetes Mellitus, Type 2 |
Novo Nordisk A/S |
2018-07-13 | PHASE4 |
| NCT04447859 | UNKNOWN | Diabetes type2 |
Tel-Aviv Sourasky Medical Center |
2020-02-23 | PHASE3 |
| NCT04615871 | UNKNOWN | Covid19; Myocardial Injury |
Vladimír Džavík |
2021-09-10 | PHASE2 |
| NCT04102189 | COMPLETED | Overweight; Obesity |
Novo Nordisk A/S |
2019-10-07 | PHASE3 |
| NCT04259801 | COMPLETED | Healthy Volunteers; Overweight; Obesity; Diabetes Mellitus, Type 2 |
Novo Nordisk A/S |
2020-02-17 | PHASE1 |
| NCT05857085 | COMPLETED | Endothelial Dysfunction; Diabetes Mellitus, Type 1; Biomarkers; Endothelial Progenitor Cells; SGLT 2 Inhibitors; Incretins; Glucose Excursions; FMD; FPF; Arterial Stiffness |
General and Teaching Hospital Celje |
2021-12-15 | PHASE4 |
| NCT04515849 | COMPLETED | Type 2 Diabetes Mellitus; Chronic Kidney Diseases |
AstraZeneca |
2020-08-31 | PHASE2 |
| NCT04524832 | COMPLETED | Diabetes Mellitus, Type 2 |
Novo Nordisk A/S |
2020-09-29 | PHASE1 |
| NCT04940078 | COMPLETED | Obesity & Overweight |
Novo Nordisk A/S |
2021-07-07 | PHASE1 |
| NCT05046873 | COMPLETED | Diabetes Mellitus, Type 2 |
Novo Nordisk A/S |
2021-09-06 | PHASE1 |
| NCT04451837 | ACTIVE_NOT_RECRUITING | Type2 Diabetes |
Region Skane |
2020-09-10 | PHASE2 |
| NCT04017832 | COMPLETED | Diabetes Mellitus, Type 2 |
Novo Nordisk A/S |
2019-07-29 | PHASE3 |
| NCT04865744 | COMPLETED | Healthy |
University of Tartu |
2021-05-19 | PHASE4 |
| NCT04109547 | COMPLETED | Diabetes Mellitus, Type 2 |
Novo Nordisk A/S |
2019-10-01 | PHASE3 |
| NCT04383197 | UNKNOWN | Type 2 Diabetes |
University of Copenhagen |
2019-12-10 | |
| NCT04878406 | COMPLETED | Healthy Volunteers Type 2 Diabetes |
Novo Nordisk A/S |
2021-05-18 | PHASE1 |
| NCT04061200 | UNKNOWN | Type 2 Diabetes With Renal Manifestations |
Steno Diabetes Center Copenhagen |
2019-11-01 | PHASE4 |
| NCT03987451 | COMPLETED | Non-alcoholic Steatohepatitis |
Novo Nordisk A/S |
2019-06-18 | PHASE2 |
| NCT03951753 | COMPLETED | Diabetes Mellitus, Type 2 |
Eli Lilly and Company |
2019-06-28 | PHASE1 |
| NCT04074161 | COMPLETED | Overweight; Obesity |
Novo Nordisk A/S |
2019-09-11 | PHASE3 |
| NCT03693430 | COMPLETED | Overweight; Obesity |
Novo Nordisk A/S |
2018-10-05 | PHASE3 |
| NCT03987919 | COMPLETED | Type 2 Diabetes |
Eli Lilly and Company |
2019-07-30 | PHASE3 |
| NCT04016974 | COMPLETED | Healthy Volunteers; Diabetes Mellitus, Type 2 |
Novo Nordisk A/S |
2019-10-08 | PHASE1 |
| NCT04109508 | COMPLETED | Healthy Volunteers; Type 2 Diabetes |
Novo Nordisk A/S |
2019-10-02 | PHASE1 |
| NCT04097600 | COMPLETED | Healthy Volunteers; Type 2 Diabetes |
Novo Nordisk A/S |
2019-09-30 | PHASE1 |
| NCT03811574 | COMPLETED | Overweight; Obesity |
Novo Nordisk A/S |
2019-01-21 | PHASE3 |
| NCT04238962 | COMPLETED | Overweight; Obesity |
Novo Nordisk A/S |
2020-02-03 | PHASE1 |
| NCT03989232 | COMPLETED | Diabetes Mellitus, Type 2 |
Novo Nordisk A/S |
2019-06-19 | PHASE3 |
| NCT03600480 | COMPLETED | Obesity; Overweight |
Novo Nordisk A/S |
2018-07-25 | PHASE1 |
| NCT04228354 | COMPLETED | Healthy Volunteers; Overweight; Obesity |
Novo Nordisk A/S |
2020-01-29 | PHASE1 |
| NCT04152915 | COMPLETED | Healthy Volunteers; Diabetes Mellitus, Type 2 |
Novo Nordisk A/S |
2019-11-25 | PHASE1 |
| NCT04263415 | COMPLETED | PCOS; Semaglutide; Taste, Altered; Tongue Tissue Transcriptome; Gastric Emptying; Central Neural Response |
University Medical Centre Ljubljana |
2019-11-02 | PHASE4 |
| NCT03552757 | COMPLETED | Obesity; Overweight |
Novo Nordisk A/S |
2018-06-04 | PHASE3 |
| NCT03357380 | COMPLETED | Hepatobiliary Disorders; Non-alcoholic Fatty Liver Disease |
Novo Nordisk A/S |
2017-11-28 | PHASE1 |
| NCT03292315 | COMPLETED | Spinal Cord Injuries; Insulin Resistance; Pre Diabetes; Obesity |
James J. Peters Veterans Affairs Medical Center |
2018-10-16 | PHASE4 |
| NCT03548987 | COMPLETED | Metabolism and Nutrition Disorder; Obesity |
Novo Nordisk A/S |
2018-06-04 | PHASE3 |
| NCT02970942 | COMPLETED | Hepatobiliary Disorders; Non-alcoholic Steatohepatitis |
Novo Nordisk A/S |
2016-11-30 | PHASE2 |
| NCT04189848 | COMPLETED | Healthy Volunteers; Diabetes Mellitus, Type 2; Overweight; Obesity |
Novo Nordisk A/S |
2019-12-03 | PHASE4 |
| NCT04143945 | COMPLETED | Healthy Volunteers Diabetes Mellitus, Type 2; Healthy Volunteers Overweight; Healthy Volunteers Obesity |
Novo Nordisk A/S |
2019-10-28 | PHASE2 |
| NCT03842202 | COMPLETED | Overweight; Obesity |
Novo Nordisk A/S |
2019-02-15 | PHASE1 |
| NCT03789578 | COMPLETED | Diabetes Mellitus, Type 2 |
Novo Nordisk A/S |
2019-01-17 | PHASE1 |
| NCT04012255 | TERMINATED | Overweight; Obesity |
Novo Nordisk A/S |
2019-07-15 | PHASE1 |
| NCT03707990 | COMPLETED | Obesity and Overweight |
Novo Nordisk A/S |
2018-10-15 | PHASE1 |
| NCT04007107 | COMPLETED | Healthy Volunteers Diabetes Mellitus, Type 2; Healthy Volunteers Overweight; Healthy Volunteers Obesity |
Novo Nordisk A/S |
2019-06-27 | PHASE2 |
| NCT03574584 | COMPLETED | Metabolism and Nutrition Disorders; Overweight or Obesity |
Novo Nordisk A/S |
2018-06-18 | PHASE1 |
| NCT03724981 | COMPLETED | Diabetes Mellitus, Type 2 |
Eli Lilly and Company |
2018-10-18 | PHASE4 |
| NCT03061214 | COMPLETED | Diabetes; Diabetes Mellitus, Type 2 |
Novo Nordisk A/S |
2017-08-28 | PHASE3 |
| NCT03611322 | COMPLETED | Diabetes Mellitus, Type 2 |
Novo Nordisk A/S |
2018-08-08 | PHASE1 |
| NCT03638778 | COMPLETED | Diabetes Mellitus, Type 2 |
Novo Nordisk A/S |
2018-08-17 | PHASE1 |
| NCT02692716 | COMPLETED | Diabetes; Diabetes Mellitus, Type 2 |
Novo Nordisk A/S |
2017-01-17 | PHASE3 |
| NCT03015220 | COMPLETED | Diabetes; Diabetes Mellitus, Type 2 |
Novo Nordisk A/S |
2017-01-10 | PHASE3 |
| NCT03288740 | COMPLETED | Diabetes; Diabetes Mellitus, Type 2 |
Novo Nordisk A/S |
2017-09-21 | PHASE1 |
| NCT03466567 | COMPLETED | Diabetes; Diabetes Mellitus, Type 2 |
Novo Nordisk A/S |
2018-03-15 | PHASE1 |
| NCT03191396 | COMPLETED | Diabetes; Diabetes Mellitus, Type 2 |
Novo Nordisk A/S |
2017-06-27 | PHASE3 |
| NCT03086330 | COMPLETED | Diabetes; Diabetes Mellitus, Type 2 |
Novo Nordisk A/S |
2017-03-15 | PHASE3 |
| NCT02827708 | COMPLETED | Diabetes; Diabetes Mellitus, Type 2 |
Novo Nordisk A/S |
2016-09-20 | PHASE3 |
| NCT02849080 | COMPLETED | Diabetes; Diabetes Mellitus, Type 2 |
Novo Nordisk A/S |
2016-09-20 | PHASE3 |
| NCT03021187 | COMPLETED | Diabetes; Diabetes Mellitus, Type 2 |
Novo Nordisk A/S |
2017-02-02 | PHASE3 |
| NCT02877355 | COMPLETED | Diabetes; Diabetes Mellitus, Type 2 |
Novo Nordisk A/S |
2016-08-22 | PHASE1 |
| NCT02906930 | COMPLETED | Diabetes; Diabetes Mellitus, Type 2 |
Novo Nordisk A/S |
2016-09-20 | PHASE3 |
| NCT02863419 | COMPLETED | Diabetes; Diabetes Mellitus, Type 2 |
Novo Nordisk A/S |
2016-08-10 | PHASE3 |
| NCT02863328 | COMPLETED | Diabetes; Diabetes Mellitus, Type 2 |
Novo Nordisk A/S |
2016-08-10 | PHASE3 |
| NCT03010475 | COMPLETED | Diabetes; Healthy |
Novo Nordisk A/S |
2017-01-05 | PHASE1 |
| NCT02920385 | COMPLETED | Diabetes; Healthy |
Novo Nordisk A/S |
2016-10-10 | PHASE1 |
| NCT02648204 | COMPLETED | Diabetes; Diabetes Mellitus, Type 2 |
Novo Nordisk A/S |
2016-01-06 | PHASE3 |
| NCT02453711 | COMPLETED | Metabolism and Nutrition Disorder; Obesity |
Novo Nordisk A/S |
2015-10-01 | PHASE2 |
| NCT02607865 | COMPLETED | Diabetes; Diabetes Mellitus, Type 2 |
Novo Nordisk A/S |
2016-02-15 | PHASE3 |
| NCT02845219 | COMPLETED | Diabetes; Diabetes Mellitus, Type 2 |
Novo Nordisk A/S |
2016-07 | PHASE1 |
| NCT02461589 | COMPLETED | Diabetes; Diabetes Mellitus, Type 2 |
Novo Nordisk A/S |
2015-09-21 | PHASE2 |
| NCT02557620 | COMPLETED | Diabetes; Healthy |
Novo Nordisk A/S |
2015-09 | PHASE1 |
| NCT01720446 | COMPLETED | Diabetes; Diabetes Mellitus, Type 2 |
Novo Nordisk A/S |
2013-02-21 | PHASE3 |
| NCT02207374 | COMPLETED | Diabetes; Diabetes Mellitus, Type 2 |
Novo Nordisk A/S |
2014-08-04 | PHASE3 |
| NCT02254291 | COMPLETED | Diabetes; Diabetes Mellitus, Type 2 |
Novo Nordisk A/S |
2014-10-02 | PHASE3 |
| NCT01930188 | COMPLETED | Diabetes; Diabetes Mellitus, Type 2 |
Novo Nordisk A/S |
2013-12-02 | PHASE3 |
| NCT02128932 | COMPLETED | Diabetes; Diabetes Mellitus, Type 2 |
Novo Nordisk A/S |
2014-08-04 | PHASE3 |
| NCT02210871 | COMPLETED | Diabetes; Diabetes Mellitus, Type 2; Hepatic Impaired |
Novo Nordisk A/S |
2014-08-07 | PHASE1 |
| NCT02147431 | COMPLETED | Diabetes; Diabetes Mellitus, Type 2 |
Novo Nordisk A/S |
2014-05-21 | PHASE1 |
| NCT02243098 | COMPLETED | Diabetes; Healthy |
Novo Nordisk A/S |
2014-09-16 | PHASE1 |
| NCT02249871 | COMPLETED | Diabetes; Healthy |
Novo Nordisk A/S |
2014-09-24 | PHASE1 |
| NCT02249910 | COMPLETED | Diabetes; Healthy |
Novo Nordisk A/S |
2014-09-18 | PHASE1 |
| NCT02016911 | COMPLETED | Diabetes; Diabetes Mellitus, Type 2; Healthy |
Novo Nordisk A/S |
2013-12-12 | PHASE1 |
| NCT02079870 | COMPLETED | Diabetes; Metabolism and Nutrition Disorder; Obesity |
Novo Nordisk A/S |
2014-03-06 | PHASE1 |
| NCT02231684 | COMPLETED | Diabetes; Healthy |
Novo Nordisk A/S |
2014-09 | PHASE1 |
| NCT02161588 | COMPLETED | Diabetes; Diabetes Mellitus, Type 2; Healthy |
Novo Nordisk A/S |
2014-06 | PHASE1 |
| NCT02014259 | COMPLETED | Diabetes; Diabetes Mellitus, Type 2; Healthy |
Novo Nordisk A/S |
2013-12-11 | PHASE1 |
| NCT02146079 | COMPLETED | Diabetes; Diabetes Mellitus, Type 2; Healthy |
Novo Nordisk A/S |
2014-05-21 | PHASE1 |
| NCT02172313 | COMPLETED | Diabetes; Healthy |
Novo Nordisk A/S |
2014-06 | PHASE1 |
| NCT02022254 | COMPLETED | Diabetes; Diabetes Mellitus, Type 2; Healthy |
Novo Nordisk A/S |
2013-12-17 | PHASE1 |
| NCT02070510 | COMPLETED | Diabetes; Healthy |
Novo Nordisk A/S |
2014-02-27 | PHASE1 |
| NCT02060266 | COMPLETED | Diabetes; Healthy |
Novo Nordisk A/S |
2014-02-04 | PHASE1 |
| NCT01866748 | COMPLETED | Diabetes; Diabetes Mellitus, Type 2; Healthy |
Novo Nordisk A/S |
2013-05 | PHASE1 |
| NCT01766245 | COMPLETED | Diabetes; Healthy |
Novo Nordisk A/S |
2012-12 | PHASE1 |
| NCT01686945 | COMPLETED | Diabetes; Diabetes Mellitus, Type 2; Healthy |
Novo Nordisk A/S |
2012-09-19 | PHASE1 |
| NCT01572753 | COMPLETED | Diabetes; Diabetes Mellitus, Type 2; Healthy |
Novo Nordisk A/S |
2012-04-12 | PHASE1 |
| NCT01619345 | COMPLETED | Diabetes; Healthy |
Novo Nordisk A/S |
2012-06 | PHASE1 |
| NCT01324505 | COMPLETED | Diabetes; Diabetes Mellitus, Type 2 |
Novo Nordisk A/S |
2011-03 | PHASE1 |
| NCT01272973 | COMPLETED | Diabetes; Diabetes Mellitus, Type 2; Healthy |
Novo Nordisk A/S |
2011-01 | PHASE1 |
| NCT00833716 | COMPLETED | Diabetes; Diabetes Mellitus, Type 2; Renal Impairment |
Novo Nordisk A/S |
2009-02-02 | PHASE1 |
| NCT00813020 | COMPLETED | Diabetes; Diabetes Mellitus, Type 2 |
Novo Nordisk A/S |
2009-01 | PHASE1 |
| NCT03144271 | COMPLETED | Diabetes; Diabetes Mellitus, Type 2; Healthy |
Novo Nordisk A/S |
2007-06-11 | PHASE1 |
(data from https://clinicaltrials.gov, updated on 2026-08-19)
Check the
Semaglutide
product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.
Mechanism and Biochemical Profile
Appendix RUO and cGMP Quality Standards
| Quality Dimension | RUO (Research Use Only) | cGMP (Current Good Manufacturing Practice) |
|---|---|---|
| Clinical Applicability | Prohibited in human clinical trials or medical diagnostics. | Mandatory for human clinical trials (Phase I–III) and therapies. |
| Regulatory Status | Non-regulated grade; exempt from drug manufacturing laws. | Legally enforced by health authorities (e.g., FDA, EMA, NMPA). |
| Facility Environment | Unclassified analytical or research laboratories. | Validated Cleanrooms (ISO Class 5–8) with continuous monitoring. |
| Quality Control | Basic purity and activity testing. | Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma). |
| Process Validation | Basic equipment calibration; no process validation required. | Full qualification (IQ/OQ/PQ) and complete batch records. |
| Quality Assurance | Vendor self-declared without required formal QMS. | Mandatory QA/QC unit, Change Control, CAPA, and vendor audits. |
| Regulatory Impact | High risk of IND rejection if used as a critical raw material. | Required for IND/NDA filings, supported by Drug Master Files (DMF). |
Footnotes
Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).
- Semaglutide Mechanism of Action: NPY/AgRP Inhibition in Hypothalamic Neurons Research
- Semaglutide Working Concentration | Cell Culture | Treatment
- Semaglutide Solubility in DMSO
- Semaglutide Stock Solution
- Semaglutide Storage
- Semaglutide Stability
- Semaglutide Combination Database
- Semaglutide Molecular Weight
- Semaglutide CAS Number
- Semaglutide Chemical Structure (2D and 3D)
- Semaglutide IC50 for Cell-based and Cell-free Assays
- Semaglutide MedChemExpress (HY-114118)? Try a better option.
- Semaglutide Cayman (40231)? Try a better option.
- Semaglutide APExBIO (C8705)? Try a better option.
- Semaglutide SDS｜MSDS
Note: Technical data last updated: Sep 1, 2026.